newsfilter
← Latest News
GlobeNewswire·

Decoy Therapeutics Named “R&D Solution of the Year” in 2026 BioTech Breakthrough Awards

  • Decoy Therapeutics was named "R&D Solution of the Year" in the sixth annual BioTech Breakthrough Awards.
  • The company's optimized pan-coronavirus lead demonstrated once-weekly dosing potential in preclinical studies during the third quarter of 2026.
  • Decoy expects to file a CTA or IND in the second half of 2027 to initiate a Phase 1 trial.
  • The IMP³ACT platform combines AI-enabled design with rapid synthesis to create Designable Multi-Antivirals (D-MAVs) that block membrane fusion.
  • The intranasal pan-coronavirus program, DCOY-CoV, targets high-risk groups including COPD patients, immunocompromised individuals, & transplant recipients.
  • CEO Rick Pierce confirmed that manufacturing & clinical partners are being lined up to advance the optimized lead candidate toward the clinic.
Company
Decoy Therapeutics, Inc
Keywords
Nasdaq:DCOY, Decoy Therapeutics, Inc